

From: HMcCollum@shionogi.com
To: [AGO - High Cost Prescription Drugs](#)
Subject: New Prescription Drug Notification
Date: Monday, February 24, 2020 12:27:40 PM
Importance: High

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To Whom It May Concern:

This is to inform you that Shionogi Inc. introduced Fetroja® (cefiderocol) (NDC 59630-0266-10) into the U.S. commercial market on February 24, 2020.

Fetroja® is an important new antibiotic for the infectious disease community and Shionogi will make every effort to ensure the infectious disease community is aware of its availability, and that patients have access. Initially, the marketing plan for the launch of Fetroja® is to promote the drug using a small institutional salesforce focused on infectious disease specialists who treat complicated urinary tract infections. In addition, Shionogi intends to contract with group purchasing organizations. The US WAC price was set at \$1,833.33 for a 10 vial pack. Fetroja® is available for open distribution. Currently, Fetroja® is only sold in the US.

The estimated national volume of patients who might be prescribed Fetroja® is not in the public domain or publicly available.

Fetroja® was granted priority review by the FDA prior to final approval. It was not granted breakthrough therapy designation.

Fetroja® was developed by Shionogi & Co., Ltd. and its affiliates.

Pursuant to 18 V.S.A. § 4637(d), the information provided herein is limited to that which is otherwise in the public domain or publicly available.

Please reply to confirm receipt.

Heather McCollum, JD MHA CCEP-I
Director, Compliance
Shionogi Inc.
300 Campus Drive
Florham Park, NJ 07932
Tel: 973.307.3888
Mobile: 973.687.2746
E-fax: 973.307.3675
Email: hmccollum@shionogi.com